A Phase I Study of LY3415244 Immunotherapy in Patients with Advanced Lung Cancer

Full Title

A Phase 1a/1b Study of LY3415244, a Bispecific Antibody in Patients with Advanced Solid Tumors


The purpose of this study is to find the highest dose of the investigational immunotherapy LY3415244 that can be given safely in patients with advanced lung cancer. LY3415244 is a “bispecific antibody.” By blocking two proteins, TIM-3 and PD-L1, it boosts antitumor activity and allows the immune system to find and kill cancer cells. Laboratory studies have shown that blocking both of these proteins at the same time is more effective than blocking either protein alone. LY3415244 is given intravenously (by vein).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have advanced or metastatic lung cancer.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Matthew Hellmann at 646-888-4863.





Disease Status

Relapsed or Refractory